AEON Biopharma

Company snapshot

AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market. This therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differe

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for AEON Biopharma. Not investment advice.

• Peer + 0 momentum

  Allergan Pharmaceuticals International

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for AEON Biopharma.

1. Jun 8, 2026 Clinical update

   Use of Mitomycin-C (MMC) in trabeculectomy — Approved

2. Jun 8, 2026 Clinical update

   Use of Mitomycin-C in trabeculectomy — Unknown

3. Jun 5, 2026 Clinical update

   ABP-450 — Phase 2

4. Jun 5, 2026 Clinical update

   ET1402L1-ARTEMIS™ T cells -IV — Phase 1

5. Jun 5, 2026 Clinical update

   autologous ET1402L1-CART cells — Phase 1

View all clinical trial activity →

• What is AEON Biopharma?

  AEON Biopharma is a biotech organization headquartered in irvine, USA. It trades on NYSE under ticker AEON. Primary therapeutic focus areas include Glaucoma, Hepatocellular Carcinoma, Cervical Dystonia, Migraine, Congenital Glaucoma. NovaPharmaNews links 9 clinical program(s), 0

• Is AEON Biopharma publicly traded?

  Yes. AEON Biopharma is listed with ticker AEON on NYSE per SEC EDGAR records linked on this profile.

• What drugs does AEON Biopharma develop or market?

  We link 8 drug profile(s) where AEON Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aeon-biopharma#company-drugs.

• What are the latest developments for AEON Biopharma?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does AEON Biopharma focus on?

  AEON Biopharma focuses on Glaucoma, Hepatocellular Carcinoma, Cervical Dystonia based on our analysis of their pipeline programs and drug development activities.